| Title |
Plant-Derived and Endogenous Cannabinoids in Epilepsy
|
|---|---|
| Published in |
Clinical Drug Investigation, February 2016
|
| DOI | 10.1007/s40261-016-0379-x |
| Pubmed ID | |
| Authors |
Alberto Verrotti, Miriam Castagnino, Mauro Maccarrone, Filomena Fezza |
| Abstract |
Cannabis is one of the oldest psychotropic drugs and its anticonvulsant properties have been known since the last century. The aim of this reveiw was to analyze the efficacy of cannabis in the treatment of epilepsy in adults and children. In addition, a description of the involvement of the endocannabinoid system in epilepsy is given in order to provide a biochemical background to the effects of endogenous cannabinoids in our body. General tolerability and adverse events associated with cannabis treatment are also investigated. Several anecdotal reports and clinical trials suggest that in the human population cannabis has anticonvulsant properties and could be effective in treating partial epilepsies and generalized tonic-clonic seizures, still known as "grand mal." They are based, among other factors, on the observation that in individuals who smoke marijuana to treat epilepsy, cessation of cannabis use precipitates the re-emergence of convulsive seizures, whereas resuming consumption of this psychotropic drug controls epilepsy in a reproducible manner. In conclusion, there is some anecdotal evidence for the potential efficacy of cannabis in treating epilepsy. Though there has been an increased effort by patients with epilepsy, their caregivers, growers, and legislators to legalize various forms of cannabis, there is still concern about its efficacy, relative potency, availability of medication-grade preparations, dosing, and potential short- and long-term side effects, including those on prenatal and childhood development. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 95 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 14% |
| Student > Ph. D. Student | 12 | 12% |
| Student > Master | 11 | 11% |
| Student > Bachelor | 11 | 11% |
| Other | 9 | 9% |
| Other | 19 | 20% |
| Unknown | 21 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 22% |
| Neuroscience | 8 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 8% |
| Psychology | 8 | 8% |
| Biochemistry, Genetics and Molecular Biology | 7 | 7% |
| Other | 19 | 20% |
| Unknown | 26 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2017.
All research outputs
#13,458,480
of 22,849,304 outputs
Outputs from Clinical Drug Investigation
#632
of 962 outputs
Outputs of similar age
#143,031
of 298,010 outputs
Outputs of similar age from Clinical Drug Investigation
#5
of 12 outputs
Altmetric has tracked 22,849,304 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 962 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,010 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.